The Fremantle Diabetes Study is a major, well constructed and hence authoritative medical research programme.
The following is a selective extract from the latest publication of on-going results.
QUOTE
Timothy M. E. Davis; Jocelyn Drinkwater; Wendy A. Davis
J Clin Endocrinol Metab. 2017;102(8):2985-2993
The PPI group of drugs is known to cause acute interstitial nephritis, which can progress sub-clinically to chronic interstitial nephritis.[3] Most cases of acute interstitial nephritis are reversible, but the development of fibrosis may herald an irreversible progression to endstage renal disease,[25] a situation that emphasizes the importance of an awareness of the nephrotoxic effects of PPIs, especially in a vulnerable population such as patients with type 2 diabetes. One animal study has, by contrast, shown that lansoprazole is associated with renoprotection,[26] an effect attributed to the anti-inflammatory and antioxidant properties of PPIs,[27] but the relevance to human disease is uncertain given the present and other data.
The PPI group of drugs has radically changed the management of acid-related diseases in recent decades, but these drugs are expensive and associated with adverse effects when used for prolonged periods.[31]
The present data provide a note of caution in the context of type 2 diabetes.
Regular assessment of their appropriateness as part of chronic pharmacotherapy, as well as regular monitoring of renal function during chronic use, appears important, and there is an argument that CVD risk factor management should be optimized if PPIs are prescribed given the present association with CVD risk after their initiation.
UNQUOTE
THESE FINDINGS SHOULD NOT BE TAKEN TO INDICATE ANY CHANGE IN CURRENT MEDICAL ADVICE NAMELY THAT THE BENEFITS OF PPI's FOR UPPER GI SURGERY PATIENTS OUTWEIGH THE POTENTIAL FOR ANY POSSIBLE LONG-TERM ADVERSE EFFECTS.